ERBB2 and breast carcinoma: In conclusion, our study demonstrates that adjuvant trastuzumab therapy in patients with early-stage HER2-positive breast cancer yields outcomes largely consistent with those reported in the APT trial, and may even be superior in certain aspects under real-world conditions.